Disclosed is an immunotherapeutic composition comprising: a) a yeast vehicle； and b) a fusion protein comprising HDV antigens, wherein the HDV antigens consist of at least one immunogenic domain of an HDV large antigen (HDAg-L) or HDV small antigen (HDAg-S), wherein the nuclear localisation sequence (NLS) has been inactivated by substitution or deletion of one or more amino acids of the NLS； wherein the composition elicits an HDV-specific immune response when administered to a subject. Also disclosed is the use of said composition in the preparation of a medicament to treat HDV infection or at least one symptom resulting from HDV infection in a subject or improve survival of a subject who is infected with HDV.
